Art

J-GLOBAL ID：202002222901132489   Reference number：20A1044680

Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma

切除不能または転移性粘膜黒色腫の患者におけるニボルマブの多施設前向き第II相試験

Author (8)： Nomura Motoo (Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan) ,  Oze Isao (Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Kyoto, Japan) ,  Masuishi Toshiki (Department of Clinical Oncology, Aichi Cancer Center Hospital, ShogoinKyoto, Japan) ,  Yokota Tomoya (Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Kyoto, Japan) ,  Satake Hironaga (Department of Medical Oncology, Kobe City Medical Center General Hospital, ShogoinKyoto, Japan) ,  Iwasawa Shunichiro (Department of Respirology, Chiba University Graduate School of Medicine, Kyoto, Japan) ,  Kato Ken (Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Kyoto, Japan) ,  Andoh Masashi (Department of Clinical Oncology, Aichi Cancer Center Hospital, ShogoinKyoto, Japan)
Material： International Journal of Clinical Oncology (Web)
Volume： 25  Issue： 5  Page： 972-977  Publication year： 2020 
JST Material Number： U1599A  ISSN： 1341-9625  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *nivolumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A1044680&from=J-GLOBAL&jstjournalNo=U1599A") }}

Author keywords (3)： Metastatic melanoma ,  Mucosal melanoma ,  Immune checkpoint inhibitor

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Skin tumors(=neoplasms)  (GF04000X) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Terms in the title (8)： 切除不能 ,  転移性 ,  粘膜 ,  黒色腫 ,  患者 ,  ニボルマブ ,  施設 ,  第II相試験